Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation
Briefings in Bioinformatics · 03.07.2026 · 27 (4)
DOI: 10.1093/bib/bbag353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 08.07.2026. Verfasst von Adi Jabarin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Agents, Deep Learning, Tetracyclines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Innovation Authority.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. In this study, we introduce a target-based deep learning framework to investigate the anticancer activity of eravacycline (Erav), a United States Food and Drug Administration (FDA)-approved antibacterial agent previously identified in our work as a potential anticancer candidate through computational screening. We developed a novel two-phase in silico yeast-based prediction model to explore potential mechanisms of action, followed by in vitro and in vivo experimental validation. DNA polymerase kappa (POLK) and mutant p53 emerged as the top-ranked candidate targets. In the studied mutant p53 PDAC model, Erav treatment significantly reduced mutant p53 protein levels and was associated with marked downregulation of POLK protein expression. POLK is a previously underexplored DNA polymerase that has been reported to be overexpressed in multiple cancer types. In a subcutaneous xenograft model, Erav treatment resulted in a 76% reduction in tumor volume. Our findings demonstrate an association between Erav treatment and reduced POLK protein expression in the studied mutant p53 PDAC model, supporting POLK as a prioritized candidate for further investigation and providing preliminary mechanistic insight into Erav activity. This integrative computational–experimental pipeline offers a robust strategy for accelerating drug repurposing in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.
- Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.
ORCID-Profile: Adi Jabarin, Guy Shtar, Eyal Mazuz
Förderung
- Israel Innovation Authority
Zitieren
APA
Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Rokach, L., & Ben-Shabat, S. (2026). Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation. Briefings in Bioinformatics, 27(4). https://doi.org/10.1093/bib/bbag353
Vancouver
Jabarin A, Shtar G, Feinshtein V, Mazuz E, Shapira B, Rokach L, et al. Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation. Briefings in Bioinformatics. 2026;27(4). doi:10.1093/bib/bbag353
BibTeX
@article{Jabarin2026,
author = {Jabarin, Adi and Shtar, Guy and Feinshtein, Valeria and Mazuz, Eyal and Shapira, Bracha and Rokach, Lior and Ben-Shabat, Shimon},
title = {Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation},
journal = {Briefings in Bioinformatics},
year = {2026},
volume = {27},
number = {4},
doi = {10.1093/bib/bbag353}
}
EUVIMED